

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Study, by Treatment (Medication, Stem Cell Transplant, Blood Transfusion), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G3B9F062AC46EN.html>

Date: January 2025

Pages: 285

Price: US\$ 4,950.00 (Single User License)

ID: G3B9F062AC46EN

Abstracts

The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market is valued at approximately USD 5.25 billion in 2023 and is projected to grow with a remarkable CAGR of 9.60%, reaching an estimated market size of USD 11.98 billion by 2032. Paroxysmal nocturnal hemoglobinuria, a rare and life-threatening blood disorder characterized by hemolysis, bone marrow failure, and thrombosis, has witnessed significant advancements in therapeutic approaches. The market for PNH treatment is driven by the rising adoption of targeted therapies, improved diagnostic capabilities, and increased awareness among healthcare professionals and patients alike. Cutting-edge developments, such as complement-inhibiting medications, have transformed the management of this condition, offering hope for a better quality of life for those affected.

The surging prevalence of PNH, coupled with the increasing focus on orphan drug development, serves as a major driving force for the market. Significant investments in research and development have led to breakthroughs in therapies, including monoclonal antibodies and next-generation complement inhibitors, which address the underlying cause of the disorder with greater precision. Furthermore, advancements in stem cell transplantation techniques, coupled with supportive government initiatives, are creating a robust pipeline of therapeutic options. However, the high costs associated with novel treatments, limited accessibility in underdeveloped regions, and the rarity of the disease pose challenges that may hinder market growth.

Regionally, North America dominates the PNH treatment market, supported by a well-established healthcare system, strong investment in pharmaceutical R&D, and the

presence of key players dedicated to developing advanced therapies. Europe follows closely, driven by increased healthcare expenditure and rising awareness about rare diseases. Meanwhile, the Asia-Pacific region is anticipated to exhibit the fastest growth during the forecast period, fueled by a growing patient population, improving healthcare infrastructure, and expanding pharmaceutical industry presence in countries like China and India. Latin America and the Middle East & Africa are also witnessing steady progress, with governments and healthcare providers working to enhance accessibility and affordability of advanced treatments.

The competitive landscape of the Global PNH Treatment Market is shaped by leading pharmaceutical companies and biotechnology firms striving to expand their portfolio of orphan drugs. Strategic collaborations, mergers, and acquisitions are prevalent as companies aim to leverage their expertise and resources to accelerate the development and commercialization of innovative therapies. The market's dynamic nature underscores the continuous pursuit of enhanced treatment modalities that offer better efficacy, safety profiles, and patient compliance.

In summary, the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market is poised for substantial growth, propelled by a combination of medical advancements, supportive policies, and increasing global awareness. The collaborative efforts of stakeholders in the healthcare ecosystem are expected to unlock new opportunities, ensuring better management and improved outcomes for PNH patients worldwide.

Major market players included in this report are:

Alexion Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Roche Holding AG

Sanofi S.A.

Novartis International AG

Pfizer Inc.

Johnson & Johnson

Amgen Inc.

Biogen Inc.

GlaxoSmithKline plc

Takeda Pharmaceutical Company Limited

CSL Behring

AstraZeneca

Bayer AG

Regeneron Pharmaceuticals, Inc.

The detailed segments and sub-segments of the market are explained below:

By Treatment

Medication

Stem Cell Transplant

Blood Transfusion

By Region: North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE (Rest of Europe)

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC (Rest of Asia Pacific)

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA (Rest of Middle East & Africa)

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional-level analysis for each market segment.

Detailed analysis of the geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approaches.

Analysis of competitive structure of the market.

Demand-side and supply-side analysis of the market.

Contents

CHAPTER 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET EXECUTIVE SUMMARY

- 1.1. Global PNH Treatment Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Treatment
 - 1.3.2. By Region
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of PNH
- 3.1.2. Increased Focus on Orphan Drug Development
- 3.1.3. Significant Investments in R&D

3.2. Market Challenges

- 3.2.1. High Cost of Novel Treatments
- 3.2.2. Limited Accessibility in Underdeveloped Regions

3.3. Market Opportunities

- 3.3.1. Expansion in Emerging Markets
- 3.3.2. Innovations in Therapeutic Approaches
- 3.3.3. Growth in Personalized Medicine

CHAPTER 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET SIZE & FORECASTS BY TREATMENT 2022-2032

5.1. Segment Dashboard

5.2. Global PNH Treatment Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

5.2.1. Medication

5.2.2. Stem Cell Transplant

5.2.3. Blood Transfusion

CHAPTER 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET SIZE & FORECASTS BY REGION 2022-2032

6.1. Segment Dashboard

6.2. Global PNH Treatment Market: Region Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

6.2.1. North America

6.2.1.1. U.S.

6.2.1.2. Canada

6.2.2. Europe

6.2.2.1. UK

6.2.2.2. Germany

6.2.2.3. France

6.2.2.4. Spain

6.2.2.5. Italy

6.2.2.6. Rest of Europe (ROE)

6.2.3. Asia Pacific

6.2.3.1. China

6.2.3.2. India

6.2.3.3. Japan

6.2.3.4. Australia

6.2.3.5. South Korea

6.2.3.6. Rest of Asia Pacific (RoAPAC)

6.2.4. Latin America

6.2.4.1. Brazil

6.2.4.2. Mexico

6.2.4.3. Rest of Latin America

6.2.5. Middle East & Africa

6.2.5.1. Saudi Arabia

6.2.5.2. South Africa

6.2.5.3. Rest of Middle East & Africa (RoMEA)

CHAPTER 7. COMPETITIVE INTELLIGENCE

7.1. Key Company SWOT Analysis

7.1.1. Alexion Pharmaceuticals, Inc.

7.1.2. Apellis Pharmaceuticals, Inc.

7.1.3. Roche Holding AG

7.2. Top Market Strategies

7.3. Company Profiles

7.3.1. Alexion Pharmaceuticals, Inc.

7.3.1.1. Key Information

7.3.1.2. Overview

7.3.1.3. Financial (Subject to Data Availability)

7.3.1.4. Product Summary

7.3.1.5. Market Strategies

7.3.2. Apellis Pharmaceuticals, Inc.

7.3.3. Roche Holding AG

7.3.4. Sanofi S.A.

7.3.5. Novartis International AG

7.3.6. Pfizer Inc.

7.3.7. Johnson & Johnson

7.3.8. Amgen Inc.

7.3.9. Biogen Inc.

7.3.10. GlaxoSmithKline plc

CHAPTER 8. RESEARCH PROCESS

8.1. Research Process

8.1.1. Data Mining

8.1.2. Analysis

8.1.3. Market Estimation

8.1.4. Validation

8.1.5. Publishing

8.2. Research Attributes

List Of Tables

LIST OF TABLES

- TABLE 1. Global PNH Treatment market, report scope
- TABLE 2. Global PNH Treatment market estimates & forecasts by Region 2022-2032 (USD Million/Billion)
- TABLE 3. Global PNH Treatment market estimates & forecasts by Treatment 2022-2032 (USD Million/Billion)
- TABLE 4. Global PNH Treatment market estimates & forecasts by Region 2022-2032 (USD Million/Billion)
- TABLE 5. Global PNH Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 6. Global PNH Treatment market by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 7. Global PNH Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 8. Global PNH Treatment market by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 9. Global PNH Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 10. Global PNH Treatment market by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 11. Global PNH Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 12. Global PNH Treatment market by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 13. Global PNH Treatment market by segment, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 14. Global PNH Treatment market by region, estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 15. U.S. PNH Treatment market estimates & forecasts, 2022-2032 (USD Million/Billion)
- TABLE 16. U.S. PNH Treatment market estimates & forecasts by Treatment 2022-2032 (USD Million/Billion)
- TABLE 17. U.S. PNH Treatment market estimates & forecasts by Region 2022-2032 (USD Million/Billion)
- TABLE 18. Canada PNH Treatment market estimates & forecasts, 2022-2032 (USD Million/Billion)

TABLE 19. Canada PNH Treatment market estimates & forecasts by Treatment
2022-2032 (USD Million/Billion)

TABLE 20. Canada PNH Treatment market estimates & forecasts by Region 2022-2032
(USD Million/Billion)

...

This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.

List Of Figures

LIST OF FIGURES

- FIG 1. Global PNH Treatment market, research methodology
- FIG 2. Global PNH Treatment market, market estimation techniques
- FIG 3. Global market size estimates & forecast methods.
- FIG 4. Global PNH Treatment market, key trends 2023
- FIG 5. Global PNH Treatment market, growth prospects 2022-2032
- FIG 6. Global PNH Treatment market, Porter's 5 force model
- FIG 7. Global PNH Treatment market, PESTEL analysis
- FIG 8. Global PNH Treatment market, value chain analysis
- FIG 9. Global PNH Treatment market by segment, 2022 & 2032 (USD Million/Billion)
- FIG 10. Global PNH Treatment market by segment, 2022 & 2032 (USD Million/Billion)
- FIG 11. Global PNH Treatment market by segment, 2022 & 2032 (USD Million/Billion)
- FIG 12. Global PNH Treatment market by segment, 2022 & 2032 (USD Million/Billion)
- FIG 13. Global PNH Treatment market by segment, 2022 & 2032 (USD Million/Billion)
- FIG 14. Global PNH Treatment market, regional snapshot 2022 & 2032
- FIG 15. North America PNH Treatment market 2022 & 2032 (USD Million/Billion)
- FIG 16. Europe PNH Treatment market 2022 & 2032 (USD Million/Billion)
- FIG 17. Asia Pacific PNH Treatment market 2022 & 2032 (USD Million/Billion)
- FIG 18. Latin America PNH Treatment market 2022 & 2032 (USD Million/Billion)
- FIG 19. Middle East & Africa PNH Treatment market 2022 & 2032 (USD Million/Billion)
- FIG 20. Global PNH Treatment market, company market share analysis (2023)

...

This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.

I would like to order

Product name: Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size Study, by Treatment (Medication, Stem Cell Transplant, Blood Transfusion), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G3B9F062AC46EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3B9F062AC46EN.html>